News
FDA says Clovis' Rubraca could be prostate cancer breakthrou...
Clovis Oncology’s Rubraca (rucaparib) has been designated as a Breakthrough Therapy by the FDA in prostate cancer, paving the way for a faster review if clinical trials work out.
